New c diff Studies
Posted: Wed May 09, 2018 12:09 am
From Dr. Colleen Kraft, Emory University
by Catherine William Stone Duff
We are currently enrolling individuals with recurrent C. difficile in 2 different microbiome therapeutics studies:
1. Title: SERES-012: ECOSPOR III: A Phase 3 Multicenter, RandomizEd, Double-Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of CLOstRidium difficile Infection (CDI) in Adults who have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI).
2. Title: SERES-013: ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI). This study is an open-label study for patients who were not successful on SERES-012.
The best number for interested patients and providers to call is 404-778-0014, or you can email us at microbiota.enrichment@emory.edu.
by Catherine William Stone Duff
We are currently enrolling individuals with recurrent C. difficile in 2 different microbiome therapeutics studies:
1. Title: SERES-012: ECOSPOR III: A Phase 3 Multicenter, RandomizEd, Double-Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of CLOstRidium difficile Infection (CDI) in Adults who have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI).
2. Title: SERES-013: ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI). This study is an open-label study for patients who were not successful on SERES-012.
The best number for interested patients and providers to call is 404-778-0014, or you can email us at microbiota.enrichment@emory.edu.